Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab vedotin or placebo with lenalidomide and rituximab for relapsed or refractory diffuse large B-cell lymphoma
NL-OMON52039Phase 3Withdrawn
- Sponsor
- Seagen Inc.
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of brentuximab vedotin, lenalidomide, rituximab and Placebo-COD Research Private Ltd in diffuse large B-cell lymphoma (DLBCL) and non-Hodgkin lymphoma (NHL) (2 arms), sponsored by Seagen Inc. Primary endpoints: Progression-free survival in the intent-to-treat population and Progression-free survival in the CD30-positive population. Planned start Nov 2020; status: withdrawn.
02
Drugs
brentuximab vedotinlenalidomiderituximabPlacebo-COD Research Private Ltd
03
Conditions
diffuse large B-cell lymphoma (DLBCL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NL-OMON52039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52039.